Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial Research Published on 2021-07-082022-10-05 Journal: Nature Medicine [Category] 바이오마커, 임상, [키워드] Administered Algorithm Analysis baseline change Clinical data conducted confidence interval double-blind Efficacy fat FGF21 fibroblast fibrosis FIVE fraction fusion protein group groups growth factor hepatic fat IMPROVE majority NASH Patient patients Placebo placebo-controlled placebo-controlled study Preclinical Randomized receive reduced reported safety profile significantly statistically significant difference steatohepatitis stratified study drug subcutaneous injection TEAE the placebo group the United State treat Treatment treatment-emergent adverse event Trial [DOI] 10.1038/s41591-021-01425-3 [Article Type] Research
Evaluation of the efficacy and safety of recombinant erythropoietin on the improvement of hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19 환자의 개선에 대한 재조합 에리트로포이에틴의 효능 및 안전성 평가: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-07-062022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 48 hours Adverse reaction Adverse reactions age approved Arm Bandar Abbas Blinding block randomization blood pressure Care checked chronic lung disease clinical clinical symptom clinical trial clinical trials Committee company comparator Patients composite endpoint control group Controlled clinical trial controls Coronary heart disease COVID-19 COVID-19 patient COVID-19 patients CRP Deep vein Deep vein thrombosis diabetes Diabetes Mellitus Diastolic blood pressure dissemination distilled water Efficacy and safety element End-stage renal disease endogenous enoxaparin erythropoietin ethics committee evaluate evaluate the effect excluded exclusion criteria expected Haemoglobin Health Health care heart disease hospitalised hospitalised COVID-19 patients Hypoxemia immune system infiltration injection intervals Intervention intervention group investigator Iran Laboratory test Laboratory tests LDH Liver disease Local Lung disease lung field lung infiltration lymphocyte Lymphocyte count lymphopenia Medical Science Medical Sciences medication minute number objective oral contraceptive outcome oxygen oxygen partial pressure oxygen saturation parallel-group partial pressure participant Patient PCR performed pharmaceutical Pharmaceutical Company Phase 2 Placebo positive Prevent principal investigator protocol randomised randomised controlled trial Randomized Randomly receive recombinant erythropoietin recruitment Registered registry renal disease reported respiratory respiratory rate Sample size saturation severe COVID-19 symptom severe COVID-19 symptoms Side effect Side effects Standard Standard of care status sterile water Study protocol subcutaneous injection subject supplementary material Systolic blood pressure tachypnea technology the ethics committee thrombosis title Treatment protocol treatment protocols Trial registration university vital signs water water for injection weakened immune system website [DOI] 10.1186/s13063-021-05363-w PMC 바로가기 [Article Type] Letter
Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot TrialArticle Published on 2021-07-012022-10-05 Journal: Chest [Category] SARS, 임상, 치료법, [키워드] 95% CI addition administration approach assigned baseline Clinical outcome clinical status Clinical status score conducted control group control subject control subjects Controlled Controlled trial COVID-19 disease dose effective enrolled Hospital stay Hospitalized hypoxemic IMPROVE improve clinical outcome Length median men moderate Open-label outcomes Patient Primary outcome progesterone Randomized Randomly receive receiving required Safe Secondary outcomes Serious Adverse Event seven-point ordinal scale severe COVID-19 severity of illness Sex Sex difference sex difference in COVID-19 outcomes sex difference in COVID-19 outcomes. Standard Standard of care subcutaneous injection subcutaneously supplemental oxygen therapeutic intervention treated Treatment Two patient women [DOI] 10.1016/j.chest.2021.02.024 PMC 바로가기 [Article Type] Article
A Peptide Vaccine Candidate Tailored to Individuals’ Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects개인의 유전학에 맞춤화된 펩타이드 백신 후보는 COVID-19 회복기 대상의 다중 표적 T 세포 면역을 모방합니다Genetics Published on 2021-06-232022-09-10 Journal: Frontiers in Genetics [Category] 비임상, [키워드] in silico clinical trial Accuracy Administered approach average BALB/c binding antibodies binding antibody Blood breath candidate CD4 CD8 Cohort Complete convalescent coronavirus COVID-19 Diseases elicit Epitopes ethnic diversity Ethnicity genotyped individuals global vaccine HLA-genotype Human immune system Immunity immunogenic implication in silico independent independent of individual individuals natural infection pathogen Pathogens peptide peptides predicted Proteins response robust SARS-CoV-2 SARS-CoV-2 immunity selected Seven structural protein structural proteins subcutaneous injection T cell T cell epitope T cell epitopes T cell response T cells transgenic mice vaccination Vaccine vaccine candidate virus-specific T cell [DOI] 10.3389/fgene.2021.684152 PMC 바로가기 [Article Type] Genetics
A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamstersResearch Article Published on 2021-05-092022-10-31 Journal: Emerging Microbes & Infections [Category] COVID-19, SARS, [키워드] Administered Body weight loss change composed COVID-19 effective Efficacy expected hamster histopathological Immunity immunodominant in vivo less linear linker-immunodominant site lung viral load natural infection Neutralizing antibody response pandemic Pneumonia PROTECT Protective SARS-CoV-2 severe COVID-19 significantly Spike protein subcutaneous injection tested the RBD the SARS-CoV-2 unlikely vaccination Vaccine vaccine candidate [DOI] 10.1080/22221751.2021.1921621 PMC 바로가기 [Article Type] Research Article
The effect of subcutaneous injection of methylprednisolone acetate and lidocaine for refractory postherpetic neuralgia: a prospective, observational studyResearch Article Published on 2021-04-082024-09-02 Journal: Health Science Reports [Category] 대상포진, [키워드] lidocaine methylprednisolone acetate refractory postherpetic neuralgia subcutaneous injection [DOI] 10.1002/hsr2.271 PMC 바로가기 [Article Type] Research Article
Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment렘데시비르(SelfExRem)의 자가 주사 가능한 연장 방출 제형: COVID-19 치료를 위한 잠재적 제형 대안Article Published on 2021-03-152022-08-31 Journal: International journal of pharmaceutics [Category] MERS, SARS, 신약개발, 진단, 치료법, 치료제, [키워드] administer analyzed approach approval autoinjector benefit biodegradable polymer Care carried Concentration coronavirus Coronavirus 2019 COVID-19 COVID-19 patients COVID19 drug Drug administration effective evaluated face-to-face contact FDA food force Frequency globe Health Health care help Hospitalization In situ depot formulations indicated injection Intravenous injection Intravenous remdesivir Long-acting injectables low molecular weight mass vaccination pandemic Patient phosphate phosphate buffer PLGA Polymer provided RDV receiving reducing Remdesivir required Research SARS-CoV2 subcutaneous injection therapeutic Treatment treatment of COVID-19 tween vaccination w/v [DOI] 10.1016/j.ijpharm.2021.120329 PMC 바로가기 [Article Type] Article
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational studyResearch Article Published on 2020-10-022022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, MERS, SARS, [키워드] accelerated adverse effect Adverse reaction alpha-2b average Clinical practice Combination Combined Combined therapy coronavirus disease COVID-19 COVID-19 infection COVID-19 patients detectable diagnosed died Efficacy and safety global pandemic high mortality hospital Hospitalization ICU IFN Infection injection intensive care interferon interferon alpha-2b intervention group laboratory-confirmed no significant difference Patient Red reduced Result significantly Subcutaneous subcutaneous injection therapy transferred treated Treatment two groups upper respiratory tract viral clearance virus Wuhan [DOI] 10.1186/s12879-020-05425-5 PMC 바로가기 [Article Type] Research Article
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-09-092022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 24 hour 7-point ordinal scale absence addition administration Admission ALT anticipated assigned AST baseline biological parameters candidate Care clinical Clinical research clinical status clinical trial clinician Comorbidity conditions Control control arm control group Coronavirus infections Council COVID 19 COVID-19 COVID-19 infection criteria current D-dimer Day death rate decrease discharge dissemination dose drug Duration early stage Efficacy element ELISA enrolment EudraCT European evaluate exclusion criteria exploratory extracorporeal membrane oxygenation Frame harmonization hospitalisation hospitalised hospitalised patient hyperinflammatory status hypersensitivity Hypothesis identify IL-6 IL-6 levels IL-6 receptor inhibitors IL-6R In-hospital incidence Inclusion inclusion criteria independent Infection Informed inhibitor interstitial pneumonia Intervention intervention group intestinal perforation Invasive mechanical ventilation investigator investigator-initiated lactation Local marker measure mechanical ventilation moderate moderate-severe neutrophil count Non-invasive non-invasive ventilation number number of death objective Open label trial outbreak outcome oxygen Oxygenation pandemic participant pathogen patients treated performed Platelet Pneumonia positive positive RT-PCR Positive test Prednisone Presence Prevent progression protocol random randomisation randomised randomised controlled trial receive recruited recruitment Registered reported requiring supplemental oxygen responsible routine clinical practice RT-PCR SAEs Sample size sarilumab SARS-CoV-2 SARS-COV-2 infection score Sepsis Serious Adverse Event serum Severe COVID-19 Infection single center single dose Spain Standard Standard of care status Study protocol Subcutaneous subcutaneous injection the patient therapy treated Treatment treatment arm treatment with tocilizumab Trial ULN union unit verbal website [DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter
Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination – A systematic review and meta-analysisMeta-Analysis Published on 2020-09-012023-06-14 Journal: Travel medicine and infectious disease [Category] Fulltext, 신종인플루엔자, [키워드] Antibody Response Drug administration routes immunisation intradermal injection Intramuscular injection subcutaneous injection [DOI] 10.1016/j.tmaid.2020.101868 PMC 바로가기 [Article Type] Meta-Analysis